Irdabisant

Drug Profile

Irdabisant

Alternative Names: CEP-26401

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Cephalon
  • Developer Teva Pharmaceutical Industries
  • Class Nootropics; Pyridazines
  • Mechanism of Action Histamine H3 receptor antagonists; Histamine H3 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in USA (PO, Liquid)
  • 01 Dec 2013 Teva Pharmaceutical Industries completes a phase I trial in Cognition disorders (in volunteers) in Netherlands (NCT01903824)
  • 01 Aug 2013 Phase-I clinical trials in Cognition disorders (in volunteers) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top